FSGS

After his former company Retrophin Inc (NASDAQ: RTRX) released positive top-line data from the Phase 2 DUET study of sparsentan, Martin Shkreli offered an olive branch to media companies wishing to speak to him on the drug he helped develop. With that, Benzinga reached out to Shkreli and...

BMO thinks Retrophin Inc (NASDAQ: RTRX) shares should touch $20 even in a worst case scenario where the upcoming Phase II DUET data for Sparsentan in FSGS delivers no benefit or unacceptable edema rates. Retrophin is BMO's top small-cap biotech pick, as it believes "shares are undervalued given...